VBCC Perspectives

Too often, palliative care, which was officially recognized as a medical specialty in 2006, is mistakenly thought to be synonymous with hospice care. Although palliative care includes the coordination of care for patients at the end of their lives, it more broadly aims to reduce patient suffering and is available to all patients with serious disease. It is designed to be given alongside active care, and certain chemotherapies have important palliative properties, including reduction in pain and nausea and improved quality of life (QOL) by the use of more tolerable dosing mechanisms.

In the December 2012 issue of Value-Based Cancer Care (VBCC), several Editorial Board members addressed the recent events surrounding the cost of cancer drugs and the reduction of the price of ziv-aflibercept (Zaltrap). VBCC continued this discussion with Al B. Benson III, MD, FACP, FASCO.

The cost of cancer care is staggering. Global sales of cancer drugs alone are forecast to grow at a rate of 12% to 15% annually, reaching $75 billion to $80 billion by the end of this year, according to IMS Health.

ASCO Annual Meeting

The surprising results of a randomized trial on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL)...

Adverse events (AEs) related to chemotherapy for metastatic breast cancer create a substantial economic burden that is primarily explained by increased inpatient...

Approximately 1 in 5 patients with cancer who are undergoing radiotherapy as part of their treatment can count on unexpected hospital stays...

Health Policy

First it was the debt ceiling, then it was the fiscal cliff, and now we have sequestration. It seems that as the weeks go by, Washington is faced with one fiscal crisis after another, with little to no progress in making a meaningful dent in the ballooning deficit. No matter what your political leanings, this has been a frustrating process to watch unfold. For the oncology team (providers and payers alike), the process has also been filled with a fair amount of nail biting as Congress considers cost-cutting measures that could impact payment rates for oncologists, cancer hospitals, and manufacturers of oncology-related medications and diagnostics.

New Orleans, LA—“We must start to think differently if we want to change the healthcare system,” said Ochsner Health System President and CEO Warner L. Thomas, CPA, MBA, FACHE, in a keynote address at the 2013 Health Information and Management Systems Society (HIMSS) annual conference. “We are seeing the most significant changes in healthcare in 30 years.”

On January 17, 2013, nearly 3 years after its initial proposed rule, the US Department of Health and Human Services (HHS) issued the long-awaited and much- anticipated HIPAA “omnibus” rule, extending the scope of the privacy law beyond providers to their business associates and subcontractors and adding increased penalties.1 Regulated entities must be in compliance with the new rules by September 22, 2013, although covered entities and business associates will have up to 1 year after the 180-day compliance date to modify existing contracts to comply with these revised rules. Oncology practices should begin examining their policies now to ensure a seamless transition to these new rules.

Value Propositions

ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) have announced the launch of a new collaboration to promote the delivery of high-quality palliative care for patients with advanced cancer. The 3-year project will focus on the complex needs of patients with advanced cancer that involve relieving cancer-related symptoms for this patient population.
 

A new immunoassay to detect the presence of 3 biomarkers is under review by the US Food and Drug Administration (FDA) and may soon become available to help the early diagnosis of renal-cell carcinoma.

Two researchers at the University of Southern California (USC) developed a new algorithm that may soon bring gene sequencing closer to clinical practice by predicting the value of DNA sequencing and making it less costly.